Hydrocortisone sodium phosphate

Hydrocortisone sodium phosphate

Pharmacological classification: glucocorticoids, mineralocorticoids
Therapeutic classification: Adrenocorticoid replacement
Consumption classification in pregnancy: Category C


pharmacology:

 

Adrenocorticoid replacement effect: Hydrocortisone is an adrenocorticoid that has glucocorticoid and mineralocorticoid properties. It is a weak anti-inflammatory drug, but its mineralocorticoid potency is as much as that of cortisone and twice as much as prednisolone or cortisone. In patients with adrenal insufficiency. It is not usually used to suppress the immune system because the doses used for this purpose are too high and will have side effects of mineralocorticoids.
Hydrocortisone sodium phosphate can be given as an intramuscular, subcutaneous, intravenous, or intravenous infusion at 12-hour intervals. The onset of action is slow but the effect is long. The injectable form is used only when the oral form cannot be used.


Pharmacokinetics:

 

Absorption: In intravenous administration, the peak effect occurs after one or two hours.
Distribution: Rapidly out of the bloodstream and spreads to muscles, liver, skin, intestines and kidneys. It is widely bound to plasma proteins (transcortin and albumin) and only the amount of drug that is not bound to the protein is active. Adrenocorticoids are secreted into milk and pass through the placenta.
Metabolism: In the liver, it is metabolized to inactive metabolites of surfactants and gluconides.
Excretion: Inactive metabolites and small amounts of unmetabolized drug are excreted by the kidneys and very small amounts of the drug are excreted in the feces. The biological half-life of hydrocortisone is 8-12 hours.


Indications:

 

• Severe inflammation, adrenal insufficiency
• Shock


prohibited usage:

 

Systemic fungal infections, high sensitivity to the components of this product


Caution:

 

Use hydrocortisone sodium phosphate with caution in the following cases:
History of myocardial infarction, ulcerative colitis, ocular herpes simplex, peptic ulcer, kidney disease, hypertension, osteoporosis, diabetes, thromboembolic disorders, seizures, myasthenia gravis, heart failure, tuberculosis, hypothyroidism, hepatic cirrhosis, tendency.


Drug interactions:

 

Barbiturates, phenytoin, or rifampin, when taken concomitantly with hydrocortisone, may reduce the corticosteroid effects of this drug due to increased hepatic metabolism. Therefore, the dose of hydrocortisone should be increased.
Hydrocortisone increases the metabolism of isoniazid and salicylates.
This medicine may cause a slight increase in blood potassium due to the use of diuretics. Low blood potassium may increase the risk of poisoning in patients taking digitalis.
Concomitant use of hydrocortisone with estrogens may reduce the tolerance of hydrocortisone.


side effects:

 

Central nerves: euphoria, insomnia, headache, psychotic behavior, seizures, dizziness
Cardiovascular: hypertension, edema, arrhythmia, thrombophlebitis, thromboembolism
Skin: Delayed wound healing, acne, skin lesions, striae, fragility, hair loss
Eyes: Cataracts, glaucoma
Gastrointestinal tract: increased appetite, nausea, vomiting, pancreatitis

Metabolic: low potassium, high blood sugar
Musculoskeletal: growth retardation in children, muscle weakness, osteoporosis
Genitourinary: Menstrual irregularities
Other complications: Acute adrenal insufficiency with increased stress (infection, surgery, trauma) or abrupt discontinuation after a long period of treatment, carbohydrate intolerance, cushingoid condition (central obesity), susceptibility to infections

 


How to store: Store away from light and at a temperature of less than 30 ° C. Protect from frost.

 

Other Products:

محصولات

Granisetron

Anticonvulsants